Table 1:
Clinical and pathologic characteristics
| Characteristic | SLN Cohort (n=118) | LND Cohort (n=96) | P† |
|---|---|---|---|
| Age (years), mean (SD) | 66.2 (±8.2) | 66.3 (±11.6) | 0.93 |
| BMI (kg/m2), mean (SD) | 29.8 (±6.6) | 30.8 (±8.2) | 0.33 |
| FIGO grade 3, n (%) | 118 (100.0%) | 96 (100.0%) | -- |
| FIGO stage (2009), n (%) | 0.38 | ||
| I | 80 (67.8%) | 70 (72.9%) | |
| II | 7 (5.9%) | 2 (2.1%) | |
| III | 31 (26.3%) | 24 (25.0%) | |
| Myometrial invasion, n (%) | 0.02 | ||
| None | 56 (47.5%) | 29 (30.2%) | |
| <50% | 34 (28.8%) | 44 (45.8%) | |
| ≥50% | 28 (23.7%) | 23 (24.0%) | |
| LVSI, n (%) | 44 (37.3%) | 25 (26.0%) | 0.08 |
| Cervical stromal invasion, n (%) | 11 (9.3%) | 4 (4.2%) | 0.14 |
| Malignant peritoneal cytology, n (%)‡ | 19/115 (16.5%) | 16/87 (18.4%) | 0.73 |
| Adjuvant therapy, n (%) | <0.001 | ||
| None | 10 (8.5%) | 22 (22.9%) | |
| IVRT | 7 (5.9%) | 27 (28.1%) | |
| EBRT ± IVRT | 1 (0.8%) | 2 (2.1%) | |
| Chemotherapy ± IVRT | 85 (72.0%) | 31 (32.3%) | |
| Chemotherapy and EBRT ± IVRT | 14 (11.9%) | 7 (7.3%) | |
| Unknown | 1 (0.8%) | 7 (7.3%) | |
SD=standard deviation, BMI=body mass index, FIGO=International Federation of Gynecology and Obstetrics, LVSI=lymphovascular space invasion, IVRT=intravaginal brachytherapy, EBRT=external beam radiation therapy.
†
Comparisons between groups were evaluated using the two-sample t test for age and BMI, and the chi-square or Fisher’s exact test for all other categorical characteristics.
‡
12 patients (3 in the SLN cohort and 9 in the LND cohort) with unknown peritoneal cytology sampling were ignored from the univariate analysis due to no peritoneal cytology sampling.